{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T01:50:01Z","timestamp":1793929801306,"version":"4.8.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"43","license":[{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10,25]]},"abstract":"<jats:p>Primary diffuse large B-cell lymphoma of the bone (PB-DLBCL) is an extremely rare type of extra-nodal lymphoma. The clinical characteristics, management, and survival outcomes of adult PB-DLBCL patients remain poorly defined. To explore the clinical manifestations, staging, therapeutic options, prognostic factors and outcomes of adult patients with PB-DLBCL and to create a model to predict survival outcomes. Data of adult PB-DLBCL patients were obtained from the Surveillance, Epidemiology, and End Results (SEER) Program 18 registries database from 2000 to 2018. The Kaplan\u2013Meier survival analysis was conducted to calculate survival rates. Univariate Cox regression, best subset selection (BESS), and least absolute shrinkage and selection operator (LASSO), followed by backward stepwise multivariable Cox regression, were used to construct the nomogram. The nomograms were evaluated using the concordance index (C-index), calibration curves and decision curve analysis (DCA). Diffuse large B-cell lymphoma (DLBCL) (67.51%) was the most frequent type of primary bone lymphoma. The most involved sites were the spine and lower-limb long bones. For the whole cohort, the 3-, 5-, 10- and 15-year overall survival (OS) rates were 74.9%, 70.5%, 60.0%, and 49.9%, and corresponding disease-specific survival (DSS) rates were 79.7%, 77.8%, 75.1%, and 71.4%, respectively. For OS, age, Ann Arbor stage, primary site and therapy were confirmed as final factors to develop the nomogram in adult PB-DLBCL patients, whereas for DSS, Age, marital status, Ann Arbor stage, number of bone lesions, therapy and year of diagnosis were confirmed as final factors in developing the nomogram. The nomograms demonstrated good accuracy and clinical utility. Established nomograms can accurately predict the survival of patients with PB-DLBCL and help clinicians optimize treatment.<\/jats:p>","DOI":"10.1097\/md.0000000000040071","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T15:05:34Z","timestamp":1730214334000},"page":"e40071","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Primary diffuse large B-cell lymphoma of bone in adults: A SEER population-based study"],"prefix":"10.1097","volume":"103","author":[{"given":"Jing","family":"Li","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Affiliated Hospital of Qingdao University, Qingdao, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangpeng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Affiliated Hospital of Qingdao University, Qingdao, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Affiliated Hospital of Qingdao University, Qingdao, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changkai","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Affiliated Hospital of Qingdao University, Qingdao, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qie","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Affiliated Hospital of Qingdao University, Qingdao, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5506-8366","authenticated-orcid":false,"given":"Donghua","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Affiliated Hospital of Qingdao University, Qingdao, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20250504","first-page":"95","article-title":"WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition.","volume":"46","author":"Jo","year":"2014","journal-title":"Pathology (Phila)"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ijrobp.2011.06.1976","article-title":"Early-stage primary bone lymphoma: a retrospective, multicenter rare cancer network (RCN) study.","volume":"83","author":"Cai","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1634\/theoncologist.2013-0249","article-title":"Clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large B-cell lymphoma of the bone (the IELSG-14 study).","volume":"19","author":"Bruno Ventre","year":"2014","journal-title":"Oncologist"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ctrv.2015.02.001","article-title":"Primary and secondary bone lymphomas.","volume":"41","author":"Messina","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/annonc\/mdl329","article-title":"A clinicopathological retrospective study of 131 patients with primary bone lymphoma: a population-based study of successively treated cohorts from the British Columbia Cancer Agency.","volume":"18","author":"Ramadan","year":"2007","journal-title":"Ann Oncol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"2040620720958538","DOI":"10.1177\/2040620720958538","article-title":"Primary lymphoma of bone: a population-based study of 2558 patients.","volume":"11","author":"Liu","year":"2020","journal-title":"Ther Adv Hematol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"100306","DOI":"10.1016\/j.jbo.2020.100306","article-title":"The incidence and mortality trends of bone lymphoma in the United States: an analysis of the surveillance, epidemiology, and end results database.","volume":"24","author":"Xu","year":"2020","journal-title":"J Bone Oncol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2147\/JBM.S350655","article-title":"Primary diffuse large B cell lymphoma of bone: a single-center experience.","volume":"13","author":"Ayesh Haj Yousef","year":"2022","journal-title":"J Blood Med"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1186\/1471-2407-14-900","article-title":"Clinical characteristics and prognostic factors of bone lymphomas: focus on the clinical significance of multifocal bone involvement by primary bone large B-cell lymphomas.","volume":"14","author":"Wu","year":"2014","journal-title":"BMC Cancer"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","article-title":"CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.","volume":"12","author":"Pfreundschuh","year":"2011","journal-title":"Lancet Oncol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ijrobp.2015.01.014","article-title":"Benefit of consolidative radiation therapy for primary bone diffuse large B-cell lymphoma.","volume":"92","author":"Tao","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1080\/10428194.2016.1177180","article-title":"Primary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studies.","volume":"57","author":"Pilorge","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2016.07.028","article-title":"Primary lymphoma of bone in the pediatric and young adult population.","volume":"60","author":"Chisholm","year":"2017","journal-title":"Hum Pathol"},{"key":"R15-20250504","first-page":"583","article-title":"Primary non-Hodgkin\u2019s lymphoma of bone in children.","volume":"88","author":"Glotzbecker","year":"2006","journal-title":"J Bone Joint Surg Am"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1200\/JCO.2007.12.9791","article-title":"How to build and interpret a nomogram for cancer prognosis.","volume":"26","author":"Iasonos","year":"2008","journal-title":"J Clin Oncol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1002\/cam4.2260","article-title":"Nomograms for predicting long-term overall survival and cancer-specific survival in lip squamous cell carcinoma: a population-based study.","volume":"8","author":"Hu","year":"2019","journal-title":"Cancer Med"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"28834","DOI":"10.1038\/srep28834","article-title":"Clinical characterization and outcome of primary bone lymphoma: a retrospective study of 61 Chinese patients.","volume":"6","author":"Zhang","year":"2016","journal-title":"Sci Rep"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/bjh.12841","article-title":"Prognostic significance of soft tissue extension, international prognostic index, and multifocality in primary bone lymphoma: a single institutional experience.","volume":"166","author":"Wu","year":"2014","journal-title":"Br J Haematol"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"116504","DOI":"10.1016\/j.envres.2023.116504","article-title":"Doxorubicin-mediated cardiac dysfunction: revisiting molecular interactions, pharmacological compounds and (nano)theranostic platforms.","volume":"234","author":"Li","year":"2023","journal-title":"Environ Res"},{"key":"R21-20250504","first-page":"1439","article-title":"Outcomes of limited stage primary bone diffuse large B-cell lymphoma in the rituximab era: a multicenter, retrospective study.","volume":"109","author":"Rezazadeh","year":"2024","journal-title":"Haematologica"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"4235939","DOI":"10.1155\/2020\/4235939","article-title":"A nomogram predicting overall and cancer-specific survival of patients with primary bone lymphoma: a large population-based study.","volume":"2020","author":"Wang","year":"2020","journal-title":"Biomed Res Int"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.clon.2012.02.006","article-title":"Primary bone lymphoma.","volume":"24","author":"Mikhaeel","year":"2012","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/annonc\/mdt482","article-title":"The clinical features, management and prognostic effects of pathological fractures in a multicenter series of 373 patients with diffuse large B-cell lymphoma of the bone.","volume":"25","author":"Govi","year":"2014","journal-title":"Ann Oncol"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1182\/blood.V128.22.3025.3025","article-title":"Long-term follow-up of primary bone biffuse large B-cell lymphoma treated with mNHL-BFM-90.","volume":"128","author":"Gabeeva","year":"2016","journal-title":"Blood"},{"key":"R26-20250504","first-page":"39","article-title":"Stage IE primary bone lymphoma: limb salvage for local recurrence.","volume":"3","author":"Jamshidi","year":"2015","journal-title":"Arch Bone Jt Surg"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/1097-0142(19830101)51:1<44::AID-CNCR2820510111>3.0.CO;2-D","article-title":"Radiation therapy for primary lymphoma of bone.","volume":"51","author":"Dosoretz","year":"1983","journal-title":"Cancer"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1002\/1097-0142(19861215)58:12<2646::AID-CNCR2820581217>3.0.CO;2-U","article-title":"Malignant lymphoma of bone.","volume":"58","author":"Ostrowski","year":"1986","journal-title":"Cancer"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.ijrobp.2003.11.020","article-title":"Primary non-Hodgkin\u2019s lymphoma of the bone: treatment and analysis of prognostic factors for Stage I and Stage II.","volume":"59","author":"Barbieri","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S0360-3016(99)00305-3","article-title":"Long-term results of combined modality therapy in primary bone lymphomas.","volume":"45","author":"Fidias","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s12288-020-01327-3","article-title":"Primary bone lymphoma: a 13 year retrospective institutional analysis in the chemo-immunotherapy era.","volume":"37","author":"Sharma","year":"2021","journal-title":"Indian J Hematol Blood Transfus"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1182\/blood.V122.21.3059.3059","article-title":"Primary bone lymphoma (PBL): impact of novel treatment on need for radiation therapy (RT), a population based study.","volume":"122","author":"Batoo","year":"2013","journal-title":"Blood"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/ijc.32391","article-title":"Second primary cancers in non-Hodgkin lymphoma: family history and survival.","volume":"146","author":"Chattopadhyay","year":"2020","journal-title":"Int J Cancer"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.3389\/fonc.2020.01157","article-title":"Role of radiation therapy differs between stages in primary bone large B-cell lymphoma in rituximab era: a population-based analysis.","volume":"10","author":"Ma","year":"2020","journal-title":"Front Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040071","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:53:05Z","timestamp":1746319985000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,25]]},"references-count":33,"journal-issue":{"issue":"43","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000040071","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,25]]}}}